[
  {
    "question": "57 years old male is brought to the clinic because of cognitive decline and multiple neurological symptoms over the last 6 months. Initially he stopped worrying about his job and started to have unusual behaviors; he leaves the house without showering, then he became apathic and paranoid. For the last month he has ataxia, frequent falls and myoclonic jerks. A brain MRI was obtained and shown. What is the most likely DX?",
    "option_a": "FTD",
    "option_b": "CJD",
    "option_c": "AD",
    "option_d": "Schizophrenia",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Creutzfeldt\u2013Jakob disease (CJD) is a rapidly progressive prion disease characterized by a constellation of cognitive, motor, and behavioral symptoms. Its rapid progression sets it apart from other neurodegenerative conditions. CJD is caused by the misfolding of the normal cellular prion protein (PrPC) into an abnormal, pathogenic form (PrPSc). This misfolded protein aggregates and induces a spongiform change in the brain parenchyma, leading to widespread neuronal loss, synaptic degeneration, and the clinical features observed. The patient\u2019s symptoms\u2014including initial behavioral changes, progressing to apathy, paranoia, ataxia, frequent falls, and myoclonic jerks\u2014fit the clinical picture of CJD. The presence of myoclonus, in particular, is a recognized hallmark of the disease. Diagnosis typically involves a combination of clinical findings, neuroimaging (MRI often shows hyperintense signals in the basal ganglia and cortical ribboning), EEG (which may reveal periodic sharp wave complexes), and cerebrospinal fluid biomarkers (e.g., 14-3-3 protein positivity and RT-QuIC assay). Differential diagnoses include frontotemporal dementia (FTD, which usually has a slower progression and lacks myoclonus), Alzheimer\u2019s disease (characterized by gradual memory decline), and autoimmune encephalitis. Currently, there is no cure or disease-modifying treatment for CJD, and management is primarily supportive with a focus on symptom control and palliative care. Given the typical age group of affected patients, pregnancy and lactation considerations are rarely applicable; however, any experimental treatments would need to be evaluated for safety in these populations. Option A (FTD) is less likely due to the rapid progression and the presence of myoclonus. Option B (CJD) correctly aligns with the clinical and imaging findings. Option C (Alzheimer\u2019s disease) generally has a more insidious onset, and Option D (Schizophrenia) does not explain the neurological signs like ataxia and myoclonus. \u2022 Rapidly progressive dementia with myoclonus is highly suggestive of CJD. \u2022 Basal ganglia involvement on MRI (hyperintense signals) is an important diagnostic clue. \u2022 RT-QuIC assay has improved diagnostic certainty. Recent advances in CSF biomarker assays, particularly RT-QuIC, have enhanced the ability to diagnose CJD early. Current recommendations continue to stress supportive care, as no effective disease-modifying therapies have emerged.",
    "exam_year": "2022",
    "exam_type": "Part I",
    "image_url": "page_13.png"
  },
  {
    "question": "41 years old male has slowly progressive cognitive decline and typical features of familial early onset Alzheimer disease. Which of the following genes is commonly linked to it?",
    "option_a": "APOE4",
    "option_b": "APP",
    "option_c": "C9ORF72",
    "option_d": "VCP gene",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Familial early-onset Alzheimer\u2019s disease is a hereditary form of Alzheimer\u2019s that typically presents before the age of 65 and is linked to mutations affecting amyloid precursor protein processing. Mutations in the APP gene, as well as PSEN1 and PSEN2, lead to abnormal processing of the amyloid precursor protein. This results in the accumulation of beta-amyloid plaques, triggering synaptic dysfunction, neuronal death, and ultimately the clinical features of Alzheimer\u2019s disease. Patients present with progressive cognitive decline that starts at a younger age than typical sporadic Alzheimer\u2019s disease. A family history of early-onset dementia strongly hints at a genetic etiology, with APP mutations being one of the common culprits. Diagnosis involves a detailed clinical assessment, neuropsychological testing, neuroimaging, and genetic testing. Differential diagnoses include late-onset sporadic Alzheimer\u2019s (where APOE4 is a risk factor rather than a direct cause), and other forms of dementia such as frontotemporal dementia, which has a different clinical profile. Management remains largely symptomatic, using cholinesterase inhibitors and NMDA receptor antagonists. Genetic counseling is essential for affected families. In pregnant or lactating women with a family history of early-onset Alzheimer\u2019s, genetic counseling and careful consideration regarding the timing of genetic testing are important, though treatments remain similar in approach. Option B (APP) is the correct answer because mutations in the APP gene are strongly associated with familial early-onset Alzheimer\u2019s. Option A (APOE4) is a risk factor for late-onset Alzheimer\u2019s and not directly causative in early-onset forms. Option C (C9ORF72) is linked with frontotemporal dementia and amyotrophic lateral sclerosis, whereas Option D (VCP gene) is associated with other multisystem proteinopathies rather than Alzheimer\u2019s disease. \u2022 Familial Alzheimer\u2019s disease typically presents before 65 years of age. \u2022 APP, along with PSEN1 and PSEN2 mutations, are commonly implicated genetic causes. \u2022 A strong family history should prompt consideration for genetic testing and counseling. Advances in genetic screening have improved early diagnosis and management strategies in familial Alzheimer\u2019s disease. Current guidelines recommend comprehensive genetic counseling and a personalized approach to symptomatic management, though disease-modifying therapies remain an area of active research.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "62 years old male with inappropriate behavior, impaired social functioning and increased tendency to eat sweets. He pays no attention to personal hygiene for the last year. Attached PET scan which shows frontal and temporal hypometabolism - what is the diagnosis?",
    "option_a": "Alzheimer frontal type",
    "option_b": "FTD",
    "option_c": "CJD",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Frontotemporal dementia (FTD) encompasses a group of disorders characterized by progressive degeneration of the frontal and/or temporal lobes, which primarily affects behavior, personality, and language. FTD is associated with the accumulation of abnormal proteins such as tau or TDP-43 leading to neuronal loss in the frontal and temporal regions. This degeneration disrupts pathways responsible for social behavior, impulse control, and executive function. The patient\u2019s presentation\u2014marked by inappropriate behavior, impaired social functioning, disinhibition (evidenced by increased sweet consumption), and neglect of personal hygiene\u2014fits the behavioral variant of FTD (bvFTD). The PET scan revealing frontal and temporal hypometabolism further supports this diagnosis. Diagnosis relies on a combination of clinical evaluation, neuropsychological assessment, and neuroimaging modalities such as PET or MRI. Differential diagnoses include Alzheimer\u2019s disease (which typically presents with memory deficits rather than prominent behavioral changes), Creutzfeldt\u2013Jakob disease (which has a more rapid course and features myoclonus), and psychiatric disorders. Management is largely supportive and focuses on behavioral modification, environmental structuring, and symptomatic pharmacotherapy. First-line approaches include non-pharmacological interventions and, when needed, second-line treatments with SSRIs or low-dose antipsychotics, keeping in mind the potential side effects. In pregnant or lactating patients, non-pharmacologic measures are preferred due to limited safety data on many psychotropic medications. Option B (FTD) is correct given the clinical and imaging findings. Option A (Alzheimer frontal type) is not a standard diagnosis and doesn\u2019t align with the characteristic PET findings. Option C (CJD) is inconsistent with the gradual progression and behavioral symptoms, and Option D is incomplete. \u2022 The behavioral variant of FTD often presents with marked changes in personality and social conduct. \u2022 PET imaging demonstrating frontal and temporal hypometabolism is a key diagnostic tool. \u2022 Early recognition facilitates better management of behavioral symptoms. Recent research has focused on refining neuroimaging criteria for early FTD diagnosis and exploring targeted therapies for tau and TDP-43 proteinopathies. Current guidelines underscore the importance of a multidisciplinary approach to managing behavioral and cognitive symptoms.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Which of the following genes is the most susceptible to develop familiar Alzheimer disease?",
    "option_a": "PSEN1",
    "option_b": "PSEN2",
    "option_c": "APP",
    "option_d": "APOE4",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Familial Alzheimer disease is an autosomal dominant neurodegenerative disorder that usually presents with early\u2010onset dementia. It is linked to mutations in several genes, with PSEN1, PSEN2, and APP being the most frequently implicated. Among these, PSEN1 mutations are the most common and have high penetrance, making this gene the most susceptible in familial Alzheimer disease. The PSEN1 gene encodes presenilin-1, a critical component of the gamma-secretase complex responsible for cleaving amyloid precursor protein (APP). Mutations in PSEN1 cause an abnormal processing of APP, leading to the overproduction of the amyloid-beta 42 peptide, which aggregates to form the amyloid plaques characteristic of Alzheimer disease. Patients with PSEN1 mutations typically present with early-onset dementia, manifesting as progressive memory loss and impairment in other cognitive domains. The aggressive course and family history are key clinical pointers toward a genetic etiology. Diagnosis is primarily clinical, supported by cognitive assessments. In cases with a strong family history suspect for early-onset Alzheimer, genetic testing is indicated. Differential diagnoses include sporadic Alzheimer disease, where risk factors like APOE4 play a role, but the genetic mutation profile differs. Current management remains symptomatic with the use of cholinesterase inhibitors (e.g., donepezil, rivastigmine) and NMDA receptor antagonists (e.g., memantine). Research into disease-modifying therapies continues. In women of childbearing age or those pregnant/lactating, the use of these medications requires a careful risk-benefit discussion, as many Alzheimer treatments are not well studied in pregnancy. Option A (PSEN1) is correct because PSEN1 mutations are the most common cause of familial Alzheimer disease. Option B (PSEN2) and Option C (APP) are associated with familial Alzheimer but are much less common. Option D (APOE4) is a genetic risk factor for sporadic Alzheimer disease rather than the highly penetrant familial form. 1. PSEN1 mutations are the most frequent genetic cause of early-onset familial Alzheimer disease. 2. Abnormal gamma-secretase activity resulting from PSEN1 mutations leads to amyloid-beta plaque accumulation. 3. Genetic counseling is essential for affected families. Recent research reinforces the predominance of PSEN1 mutations in familial Alzheimer disease. Ongoing studies are exploring gamma-secretase modulators and other targeted therapies, although current treatment remains largely symptomatic.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "52 years old male brought to the ED after he experienced abnormal behavioral changes that started acutely. On examination, he is alert and oriented to self but repeat the same questions over and over. His memory is affected for the recent events but he was able to remember the old events. He has intact attention, speech and language domains. His symptoms disappeared completely after 4 hours. No other signs or symptoms. What is the best next step?",
    "option_a": "Brain CT/CTA",
    "option_b": "EEG",
    "option_c": "Urine toxicology",
    "option_d": "Reassurance/send him home",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Dementia",
    "explanation": "Familial Alzheimer disease is an autosomal dominant neurodegenerative disorder that usually presents with early\u2010onset dementia. It is linked to mutations in several genes, with PSEN1, PSEN2, and APP being the most frequently implicated. Among these, PSEN1 mutations are the most common and have high penetrance, making this gene the most susceptible in familial Alzheimer disease. The PSEN1 gene encodes presenilin-1, a critical component of the gamma-secretase complex responsible for cleaving amyloid precursor protein (APP). Mutations in PSEN1 cause an abnormal processing of APP, leading to the overproduction of the amyloid-beta 42 peptide, which aggregates to form the amyloid plaques characteristic of Alzheimer disease. Patients with PSEN1 mutations typically present with early-onset dementia, manifesting as progressive memory loss and impairment in other cognitive domains. The aggressive course and family history are key clinical pointers toward a genetic etiology. Diagnosis is primarily clinical, supported by cognitive assessments. In cases with a strong family history suspect for early-onset Alzheimer, genetic testing is indicated. Differential diagnoses include sporadic Alzheimer disease, where risk factors like APOE4 play a role, but the genetic mutation profile differs. Current management remains symptomatic with the use of cholinesterase inhibitors (e.g., donepezil, rivastigmine) and NMDA receptor antagonists (e.g., memantine). Research into disease-modifying therapies continues. In women of childbearing age or those pregnant/lactating, the use of these medications requires a careful risk-benefit discussion, as many Alzheimer treatments are not well studied in pregnancy. Option A (PSEN1) is correct because PSEN1 mutations are the most common cause of familial Alzheimer disease. Option B (PSEN2) and Option C (APP) are associated with familial Alzheimer but are much less common. Option D (APOE4) is a genetic risk factor for sporadic Alzheimer disease rather than the highly penetrant familial form. 1. PSEN1 mutations are the most frequent genetic cause of early-onset familial Alzheimer disease. 2. Abnormal gamma-secretase activity resulting from PSEN1 mutations leads to amyloid-beta plaque accumulation. 3. Genetic counseling is essential for affected families. Recent research reinforces the predominance of PSEN1 mutations in familial Alzheimer disease. Ongoing studies are exploring gamma-secretase modulators and other targeted therapies, although current treatment remains largely symptomatic.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "76 years old male with unsteady gait, cognitive decline and urinary incontinence started 1 year ago. Brain MRI shows extensive subcortical white matter disease. Diagnosis?",
    "option_a": "Binswanger disease",
    "option_b": "DLB",
    "option_c": "NPH",
    "option_d": "depression",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Familial Alzheimer disease is an autosomal dominant neurodegenerative disorder that usually presents with early\u2010onset dementia. It is linked to mutations in several genes, with PSEN1, PSEN2, and APP being the most frequently implicated. Among these, PSEN1 mutations are the most common and have high penetrance, making this gene the most susceptible in familial Alzheimer disease. The PSEN1 gene encodes presenilin-1, a critical component of the gamma-secretase complex responsible for cleaving amyloid precursor protein (APP). Mutations in PSEN1 cause an abnormal processing of APP, leading to the overproduction of the amyloid-beta 42 peptide, which aggregates to form the amyloid plaques characteristic of Alzheimer disease. Patients with PSEN1 mutations typically present with early-onset dementia, manifesting as progressive memory loss and impairment in other cognitive domains. The aggressive course and family history are key clinical pointers toward a genetic etiology. Diagnosis is primarily clinical, supported by cognitive assessments. In cases with a strong family history suspect for early-onset Alzheimer, genetic testing is indicated. Differential diagnoses include sporadic Alzheimer disease, where risk factors like APOE4 play a role, but the genetic mutation profile differs. Current management remains symptomatic with the use of cholinesterase inhibitors (e.g., donepezil, rivastigmine) and NMDA receptor antagonists (e.g., memantine). Research into disease-modifying therapies continues. In women of childbearing age or those pregnant/lactating, the use of these medications requires a careful risk-benefit discussion, as many Alzheimer treatments are not well studied in pregnancy. Option A (PSEN1) is correct because PSEN1 mutations are the most common cause of familial Alzheimer disease. Option B (PSEN2) and Option C (APP) are associated with familial Alzheimer but are much less common. Option D (APOE4) is a genetic risk factor for sporadic Alzheimer disease rather than the highly penetrant familial form. 1. PSEN1 mutations are the most frequent genetic cause of early-onset familial Alzheimer disease. 2. Abnormal gamma-secretase activity resulting from PSEN1 mutations leads to amyloid-beta plaque accumulation. 3. Genetic counseling is essential for affected families. Recent research reinforces the predominance of PSEN1 mutations in familial Alzheimer disease. Ongoing studies are exploring gamma-secretase modulators and other targeted therapies, although current treatment remains largely symptomatic.",
    "exam_year": "2022",
    "exam_type": "Part I",
    "image_url": "page_12.png"
  },
  {
    "question": "36 years old female referred to neurology clinic for issues with forgetting the events. She has chronic migraine headache and had suffered stroke in the past. Her father died at age of 65 with dementia. What is the best diagnostic test to reach DX?",
    "option_a": "Brain MRI/MRA",
    "option_b": "Biopsy for osmophilic material",
    "option_c": "LP",
    "option_d": "Lactate/pyruvate",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Familial Alzheimer disease is an autosomal dominant neurodegenerative disorder that usually presents with early\u2010onset dementia. It is linked to mutations in several genes, with PSEN1, PSEN2, and APP being the most frequently implicated. Among these, PSEN1 mutations are the most common and have high penetrance, making this gene the most susceptible in familial Alzheimer disease. The PSEN1 gene encodes presenilin-1, a critical component of the gamma-secretase complex responsible for cleaving amyloid precursor protein (APP). Mutations in PSEN1 cause an abnormal processing of APP, leading to the overproduction of the amyloid-beta 42 peptide, which aggregates to form the amyloid plaques characteristic of Alzheimer disease. Patients with PSEN1 mutations typically present with early-onset dementia, manifesting as progressive memory loss and impairment in other cognitive domains. The aggressive course and family history are key clinical pointers toward a genetic etiology. Diagnosis is primarily clinical, supported by cognitive assessments. In cases with a strong family history suspect for early-onset Alzheimer, genetic testing is indicated. Differential diagnoses include sporadic Alzheimer disease, where risk factors like APOE4 play a role, but the genetic mutation profile differs. Current management remains symptomatic with the use of cholinesterase inhibitors (e.g., donepezil, rivastigmine) and NMDA receptor antagonists (e.g., memantine). Research into disease-modifying therapies continues. In women of childbearing age or those pregnant/lactating, the use of these medications requires a careful risk-benefit discussion, as many Alzheimer treatments are not well studied in pregnancy. Option A (PSEN1) is correct because PSEN1 mutations are the most common cause of familial Alzheimer disease. Option B (PSEN2) and Option C (APP) are associated with familial Alzheimer but are much less common. Option D (APOE4) is a genetic risk factor for sporadic Alzheimer disease rather than the highly penetrant familial form. 1. PSEN1 mutations are the most frequent genetic cause of early-onset familial Alzheimer disease. 2. Abnormal gamma-secretase activity resulting from PSEN1 mutations leads to amyloid-beta plaque accumulation. 3. Genetic counseling is essential for affected families. Recent research reinforces the predominance of PSEN1 mutations in familial Alzheimer disease. Ongoing studies are exploring gamma-secretase modulators and other targeted therapies, although current treatment remains largely symptomatic.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "A 77-year-old-man came with his wife to clinic with 3 years history of personality changes and cognitive impairment. She reported that he keeps seeing small animals around him and he moves a lot while he is sleeping. There are days where he is extremely confused and agitated and days where he is closer to his prior baseline.\nWhat is the most likely diagnosis?",
    "option_a": "Lewy body dementia",
    "option_b": "Alzheimer\u2019s disease",
    "option_c": "Schizophrenia",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Lewy body dementia (LBD) is a neurodegenerative disorder marked by a triad of symptoms: fluctuating cognition, recurrent visual hallucinations, and parkinsonian motor features. This condition typically presents in older adults and is recognized by its characteristic fluctuating course and early neuropsychiatric manifestations. The disease is characterized by the abnormal accumulation of \u03b1\u2010synuclein protein in the form of Lewy bodies within cortical and subcortical neurons. This deposition leads to disruptions in neurotransmitter systems, particularly cholinergic and dopaminergic pathways, which account for the cognitive fluctuations and motor symptoms. Recent evidence supports the idea that these deposits may initially spare the medial temporal lobes compared to Alzheimer\u2019s disease, resulting in comparatively less severe memory deficits early on. In the presented case, the patient's personality changes, visual hallucinations (seeing small animals), and abnormal motor activity during sleep (which may reflect REM sleep behavior disorder) are all hallmark features of LBD. The fluctuation between days of marked confusion and near-baseline functioning further supports this diagnosis, distinguishing it from more steadily progressive dementias like Alzheimer\u2019s disease. The diagnosis is primarily clinical, utilizing consensus criteria that emphasize cognitive fluctuations, early visual hallucinations, and parkinsonism. Ancillary tests include dopaminergic transporter imaging (DAT SPECT) to support the diagnosis by demonstrating reduced uptake in the basal ganglia. Differential diagnoses include Alzheimer\u2019s disease (which typically presents with early memory impairment), vascular dementia (often associated with stepwise decline), and primary psychiatric disorders, which usually do not explain the parkinsonian and REM sleep behavior features. First\u2010line management involves symptomatic treatment. Cholinesterase inhibitors (e.g., rivastigmine) are commonly used to improve cognitive function and control hallucinations. Caution is advised with antipsychotics due to the risk of severe neuroleptic sensitivity. Nonpharmacological strategies, caregiver support, and environmental modifications are also crucial. Although pregnancy and lactation concerns are largely irrelevant given the typical age of onset, in younger patients any medication usage must be cautiously balanced against potential risks. Option A (Lewy body dementia) is correct. Option B (Alzheimer\u2019s disease) is less likely because Alzheimer\u2019s usually presents with predominant memory loss and does not characteristically show visual hallucinations or REM sleep behavior disturbances early on. Option C (Schizophrenia) is very unlikely in a 77\u2010year\u2010old with fluctuating cognition and parkinsonian features. 1. Fluctuating cognitive status accompanied by early visual hallucinations and REM sleep disturbances is highly suggestive of LBD. 2. Patients with LBD show marked sensitivity to antipsychotics; hence, medication choices must be made with extreme caution. Recent studies have validated the use of DAT imaging in the diagnosis of LBD, and current clinical guidelines continue to recommend cholinesterase inhibitors for managing cognitive and neuropsychiatric symptoms. Ongoing research is exploring biomarkers and neuroprotective strategies to better address the disease progression.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Which of the following genes is associated with familial Alzheimer's disease?",
    "option_a": "APP",
    "option_b": "Apolipoprotein E",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Lewy body dementia (LBD) is a neurodegenerative disorder marked by a triad of symptoms: fluctuating cognition, recurrent visual hallucinations, and parkinsonian motor features. This condition typically presents in older adults and is recognized by its characteristic fluctuating course and early neuropsychiatric manifestations. The disease is characterized by the abnormal accumulation of \u03b1\u2010synuclein protein in the form of Lewy bodies within cortical and subcortical neurons. This deposition leads to disruptions in neurotransmitter systems, particularly cholinergic and dopaminergic pathways, which account for the cognitive fluctuations and motor symptoms. Recent evidence supports the idea that these deposits may initially spare the medial temporal lobes compared to Alzheimer\u2019s disease, resulting in comparatively less severe memory deficits early on. In the presented case, the patient's personality changes, visual hallucinations (seeing small animals), and abnormal motor activity during sleep (which may reflect REM sleep behavior disorder) are all hallmark features of LBD. The fluctuation between days of marked confusion and near-baseline functioning further supports this diagnosis, distinguishing it from more steadily progressive dementias like Alzheimer\u2019s disease. The diagnosis is primarily clinical, utilizing consensus criteria that emphasize cognitive fluctuations, early visual hallucinations, and parkinsonism. Ancillary tests include dopaminergic transporter imaging (DAT SPECT) to support the diagnosis by demonstrating reduced uptake in the basal ganglia. Differential diagnoses include Alzheimer\u2019s disease (which typically presents with early memory impairment), vascular dementia (often associated with stepwise decline), and primary psychiatric disorders, which usually do not explain the parkinsonian and REM sleep behavior features. First\u2010line management involves symptomatic treatment. Cholinesterase inhibitors (e.g., rivastigmine) are commonly used to improve cognitive function and control hallucinations. Caution is advised with antipsychotics due to the risk of severe neuroleptic sensitivity. Nonpharmacological strategies, caregiver support, and environmental modifications are also crucial. Although pregnancy and lactation concerns are largely irrelevant given the typical age of onset, in younger patients any medication usage must be cautiously balanced against potential risks. Option A (Lewy body dementia) is correct. Option B (Alzheimer\u2019s disease) is less likely because Alzheimer\u2019s usually presents with predominant memory loss and does not characteristically show visual hallucinations or REM sleep behavior disturbances early on. Option C (Schizophrenia) is very unlikely in a 77\u2010year\u2010old with fluctuating cognition and parkinsonian features. 1. Fluctuating cognitive status accompanied by early visual hallucinations and REM sleep disturbances is highly suggestive of LBD. 2. Patients with LBD show marked sensitivity to antipsychotics; hence, medication choices must be made with extreme caution. Recent studies have validated the use of DAT imaging in the diagnosis of LBD, and current clinical guidelines continue to recommend cholinesterase inhibitors for managing cognitive and neuropsychiatric symptoms. Ongoing research is exploring biomarkers and neuroprotective strategies to better address the disease progression.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with fluent speech, impaired comprehension, naming, and repetition. Where is the lesion?",
    "option_a": "Frontoparietal operculum.",
    "option_b": "Posterior perisylvian temporal",
    "option_c": "Posterior-inferior temporal",
    "option_d": "Occipital lobe",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "The patient\u2019s fluent speech accompanied by impaired comprehension, naming, and repetition is characteristic of Wernicke\u2019s aphasia. This aphasia variant results from damage to the language comprehension area (Wernicke\u2019s area), which is typically located in the posterior perisylvian region of the left temporal lobe. Wernicke\u2019s aphasia is most commonly due to an ischemic stroke in the territory of the left middle cerebral artery (MCA), which supplies the posterior superior temporal gyrus. Injury to this region disrupts the neural circuits that mediate the comprehension and integration of auditory language, leading to fluent but often nonsensical speech with impaired repetition and naming. Patients with Wernicke\u2019s aphasia present with fluent, yet often jargoned, speech along with significant difficulties in grasping the meaning of words and sentences. Although their spontaneous speech is effortless, they usually produce paraphasic errors. This pattern distinctly contrasts with Broca\u2019s aphasia, where speech is nonfluent, and conduction aphasia, which typically maintains comprehension despite repetition difficulties. The clinical diagnosis is based on a thorough language assessment that identifies fluent speech with impaired comprehension, repetition, and naming. Neuroimaging (CT/MRI) is essential to confirm a lesion in the left posterior perisylvian temporal region. Differential diagnoses include conduction aphasia (fluent speech with preserved comprehension but impaired repetition) and global aphasia (both comprehension and speech production are severely affected). Acute management focuses on addressing the underlying cause, commonly ischemic stroke, with standard stroke protocols. This may include thrombolytic therapy if the patient presents within the critical time window, with special considerations for pregnant patients where imaging choices (prefer non-ionizing modalities if possible) and medication safety profiles (e.g., careful use of thrombolytics and antiplatelets) are mandatory. Long-term management involves targeted speech and language rehabilitation to improve recovery. When managing pregnant or lactating patients, it is essential to choose therapies that are safe and do not compromise fetal or neonatal health. Option A (Frontoparietal operculum) is typically associated with Broca\u2019s aphasia, which presents with nonfluent speech. Option C (Posterior-inferior temporal) may affect semantic processing but does not classically present with all the deficits described. Option D (Occipital lobe) is unrelated to language processing. Hence, Option B (Posterior perisylvian temporal) best corresponds to the typical localization of Wernicke\u2019s aphasia. 1. Fluent but nonsensical speech with poor comprehension is a hallmark of Wernicke\u2019s aphasia. 2. The lesion is typically in the posterior perisylvian temporal region of the left hemisphere. 3. Accurate localization via neuroimaging is vital for guiding both acute stroke management and rehabilitation. 4. Special populations such as pregnant or lactating women require modifications in imaging and treatment strategies to ensure safety. Recent studies support early and intensive speech therapy based on neuroplasticity principles for recovery in aphasia. Guidelines from the American Heart Association and American Stroke Association emphasize rapid assessment and treatment of ischemic strokes, with adaptations recommended for pregnant and lactating patients to minimize risks. The efficacy of targeted neurorehabilitation for language recovery has been well documented, underscoring the importance of early intervention.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "A Middle-aged male who presented to the outpatient clinic by his father, which he stat patient in the last few months had changed, he is slower in (cognitive function) and recently had change in personality becoming easily agitated, Past history of motor vehicle accident 3 years ago that result in 3 days of ICU admission. What is the appropriate next step?",
    "option_a": "EEG",
    "option_b": "PET-FTD",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "This case describes a middle\u2010aged male with a recent decline in cognitive speed and a marked change in personality \u2013 features that are highly suggestive of a behavioral variant of frontotemporal dementia (bv\u2010FTD). Although the patient has a history of traumatic brain injury, the progressive and specific nature of his behavioral and executive dysfunction points more towards a neurodegenerative process. Frontotemporal dementia results from degeneration of the frontal and temporal lobes with selective loss of neurons and glial cells. It is often associated with abnormal protein accumulations (such as tau or TDP-43) which result in the characteristic atrophy and hypometabolism seen in these areas on functional imaging. The patient\u2019s complaints \u2013 slowed cognitive function, personality change, and increased agitation \u2013 are classic for bv-FTD. While Alzheimer\u2019s disease usually begins with memory deficits, bv-FTD is predominantly characterized by alterations in behavior and executive function. The past head trauma is acknowledged but is less likely to account for an insidious progression over months with these specific features. Evaluation of suspected FTD typically begins with a thorough history, neuropsychological assessment, and neuroimaging. While structural imaging (MRI) is generally the first step, functional imaging such as FDG-PET can be particularly useful when the clinical picture is unclear, as it demonstrates characteristic patterns of hypometabolism in the frontal and anterior temporal regions. In this question, among the available options, PET-FTD is the investigation of choice to support the diagnosis. There is no cure for FTD; management focuses on symptomatic treatment and supportive care. Behavioral symptoms may be managed with selective serotonin reuptake inhibitors (SSRIs) and other psychotropic medications, and patients benefit from cognitive rehabilitation and caregiver support. For women who are pregnant or lactating (not applicable in this male patient but relevant in general), careful consideration is given to medication choices to avoid teratogenic risks \u2013 for instance, avoiding medications with high fetal risk profiles and opting for non-pharmacological measures when possible. Additionally, radiation exposure from PET scans is generally avoided during pregnancy. Option A (EEG) is more useful in evaluating seizure activity or encephalopathic states, not neurodegenerative dementias. The marked Option B (PET-FTD), likely shorthand for an FDG-PET scan aimed at evaluating frontotemporal metabolic patterns, is more directly aligned with confirming a diagnosis of bv-FTD. Options C and D are not provided, so within the given alternatives, B stands as the best choice. In middle-aged patients presenting with marked personality changes and executive dysfunction, consider bv-FTD over other types of dementia. FDG-PET is a highly useful tool in ambiguous cases, providing metabolic evidence of frontotemporal involvement. A history of head trauma should be noted but does not usually account for the slow, progressive nature of the symptomatology seen in bv-FTD. Recent guidelines and studies support the role of functional imaging in the assessment of frontotemporal dementia. FDG-PET has been validated to show hypometabolism localized to the frontal and temporal lobes, adding a sensitive and specific tool to the diagnostic work-up when clinical features are suggestive. While MRI remains a standard initial imaging modality, FDG-PET is particularly valuable in confirming the diagnosis when structural changes are subtle or atypical.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Young man with family history of early onset Alzheimer disease. Which of the following genes increases the risk of Sporadic Alzheimer disease?",
    "option_a": "APP",
    "option_b": "Apolipoprotein E",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Alzheimer's disease has both familial and sporadic forms. Familial early\u2010onset Alzheimer\u2019s is linked to mutations in genes such as APP, PSEN1, and PSEN2, whereas sporadic Alzheimer\u2019s most commonly has a risk factor in the Apolipoprotein E (APOE) gene. Specifically, the APOE \u03b54 allele is known to increase the risk of developing sporadic Alzheimer\u2019s disease. APOE is involved in lipid transport and neuronal repair as well as in amyloid\u2010\u03b2 metabolism. The \u03b54 allele is less effective at clearing amyloid\u2010\u03b2, which contributes to its accumulation and plaque formation, a central mechanism in Alzheimer\u2019s pathology. In contrast, mutations in the APP gene lead to abnormal amyloid precursor protein processing and are more frequently implicated in familial cases. Patients with a family history of early-onset Alzheimer\u2019s often worry about their own risk. In sporadic Alzheimer\u2019s, although the disease typically appears later in life, carrying the APOE \u03b54 allele significantly increases the risk. Clinically, Alzheimer\u2019s disease presents with progressive memory loss, executive dysfunction, and other cognitive deficits. Diagnosis is based on clinical assessment, supported by neuroimaging (MRI or PET scans) and sometimes cerebrospinal fluid biomarkers. Differential diagnoses include vascular dementia, frontotemporal dementia, and Lewy body dementia. Each can be differentiated based on clinical course, imaging patterns, and additional features (e.g., motor symptoms in Lewy body dementia). Current management includes cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and NMDA receptor antagonists (memantine) as first-line treatment. Non-pharmacologic interventions like cognitive therapy and caregiver support are also recommended. In pregnancy and lactation, pharmacologic management is limited due to potential safety concerns, so emphasis is on non-drug supportive measures. Option A (APP) is primarily associated with familial Alzheimer\u2019s rather than the sporadic form. Option B (Apolipoprotein E) is correct because the APOE \u03b54 allele significantly raises the risk of sporadic Alzheimer\u2019s. Options C and D are not provided. \u2022 The APOE \u03b54 allele is a well-established risk factor for sporadic Alzheimer\u2019s disease.  \u2022 Mutations in the APP gene are implicated in familial early-onset Alzheimer\u2019s. Recent studies continue to show a strong association between the APOE \u03b54 allele and increased amyloid-\u03b2 deposition, reinforcing its role as a major risk factor for sporadic Alzheimer\u2019s. Emerging research is also focused on how modulating APOE expression might offer new therapeutic avenues.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "What is the most common memory type affected in Korsakov's encephalopathy?",
    "option_a": "Episodic memory",
    "option_b": "Declarative",
    "option_c": "Working",
    "option_d": "Semantic",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Alzheimer's disease has both familial and sporadic forms. Familial early\u2010onset Alzheimer\u2019s is linked to mutations in genes such as APP, PSEN1, and PSEN2, whereas sporadic Alzheimer\u2019s most commonly has a risk factor in the Apolipoprotein E (APOE) gene. Specifically, the APOE \u03b54 allele is known to increase the risk of developing sporadic Alzheimer\u2019s disease. APOE is involved in lipid transport and neuronal repair as well as in amyloid\u2010\u03b2 metabolism. The \u03b54 allele is less effective at clearing amyloid\u2010\u03b2, which contributes to its accumulation and plaque formation, a central mechanism in Alzheimer\u2019s pathology. In contrast, mutations in the APP gene lead to abnormal amyloid precursor protein processing and are more frequently implicated in familial cases. Patients with a family history of early-onset Alzheimer\u2019s often worry about their own risk. In sporadic Alzheimer\u2019s, although the disease typically appears later in life, carrying the APOE \u03b54 allele significantly increases the risk. Clinically, Alzheimer\u2019s disease presents with progressive memory loss, executive dysfunction, and other cognitive deficits. Diagnosis is based on clinical assessment, supported by neuroimaging (MRI or PET scans) and sometimes cerebrospinal fluid biomarkers. Differential diagnoses include vascular dementia, frontotemporal dementia, and Lewy body dementia. Each can be differentiated based on clinical course, imaging patterns, and additional features (e.g., motor symptoms in Lewy body dementia). Current management includes cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and NMDA receptor antagonists (memantine) as first-line treatment. Non-pharmacologic interventions like cognitive therapy and caregiver support are also recommended. In pregnancy and lactation, pharmacologic management is limited due to potential safety concerns, so emphasis is on non-drug supportive measures. Option A (APP) is primarily associated with familial Alzheimer\u2019s rather than the sporadic form. Option B (Apolipoprotein E) is correct because the APOE \u03b54 allele significantly raises the risk of sporadic Alzheimer\u2019s. Options C and D are not provided. \u2022 The APOE \u03b54 allele is a well-established risk factor for sporadic Alzheimer\u2019s disease.  \u2022 Mutations in the APP gene are implicated in familial early-onset Alzheimer\u2019s. Recent studies continue to show a strong association between the APOE \u03b54 allele and increased amyloid-\u03b2 deposition, reinforcing its role as a major risk factor for sporadic Alzheimer\u2019s. Emerging research is also focused on how modulating APOE expression might offer new therapeutic avenues.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Male patient brought to the hospital by his wife for forgetfulness issue. He has difficulty with speech expression with his friends that made his social life difficult. On examination, he couldn\u2019t recall 3 items on MMSE. He has impaired naming, repetition, with intact comprehension. Which of the following is the most likely diagnosis?",
    "option_a": "Semantic dementia",
    "option_b": "Primary progressive palsy",
    "option_c": "Frontotemporal lobe dementia",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Alzheimer's disease has both familial and sporadic forms. Familial early\u2010onset Alzheimer\u2019s is linked to mutations in genes such as APP, PSEN1, and PSEN2, whereas sporadic Alzheimer\u2019s most commonly has a risk factor in the Apolipoprotein E (APOE) gene. Specifically, the APOE \u03b54 allele is known to increase the risk of developing sporadic Alzheimer\u2019s disease. APOE is involved in lipid transport and neuronal repair as well as in amyloid\u2010\u03b2 metabolism. The \u03b54 allele is less effective at clearing amyloid\u2010\u03b2, which contributes to its accumulation and plaque formation, a central mechanism in Alzheimer\u2019s pathology. In contrast, mutations in the APP gene lead to abnormal amyloid precursor protein processing and are more frequently implicated in familial cases. Patients with a family history of early-onset Alzheimer\u2019s often worry about their own risk. In sporadic Alzheimer\u2019s, although the disease typically appears later in life, carrying the APOE \u03b54 allele significantly increases the risk. Clinically, Alzheimer\u2019s disease presents with progressive memory loss, executive dysfunction, and other cognitive deficits. Diagnosis is based on clinical assessment, supported by neuroimaging (MRI or PET scans) and sometimes cerebrospinal fluid biomarkers. Differential diagnoses include vascular dementia, frontotemporal dementia, and Lewy body dementia. Each can be differentiated based on clinical course, imaging patterns, and additional features (e.g., motor symptoms in Lewy body dementia). Current management includes cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and NMDA receptor antagonists (memantine) as first-line treatment. Non-pharmacologic interventions like cognitive therapy and caregiver support are also recommended. In pregnancy and lactation, pharmacologic management is limited due to potential safety concerns, so emphasis is on non-drug supportive measures. Option A (APP) is primarily associated with familial Alzheimer\u2019s rather than the sporadic form. Option B (Apolipoprotein E) is correct because the APOE \u03b54 allele significantly raises the risk of sporadic Alzheimer\u2019s. Options C and D are not provided. \u2022 The APOE \u03b54 allele is a well-established risk factor for sporadic Alzheimer\u2019s disease.  \u2022 Mutations in the APP gene are implicated in familial early-onset Alzheimer\u2019s. Recent studies continue to show a strong association between the APOE \u03b54 allele and increased amyloid-\u03b2 deposition, reinforcing its role as a major risk factor for sporadic Alzheimer\u2019s. Emerging research is also focused on how modulating APOE expression might offer new therapeutic avenues.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Case of Gerstman feature what is the associated language deficit?",
    "option_a": "Anomic aphasia",
    "option_b": "Wernicke's aphasia",
    "option_c": "Transcortical motor aphasia",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Alzheimer's disease has both familial and sporadic forms. Familial early\u2010onset Alzheimer\u2019s is linked to mutations in genes such as APP, PSEN1, and PSEN2, whereas sporadic Alzheimer\u2019s most commonly has a risk factor in the Apolipoprotein E (APOE) gene. Specifically, the APOE \u03b54 allele is known to increase the risk of developing sporadic Alzheimer\u2019s disease. APOE is involved in lipid transport and neuronal repair as well as in amyloid\u2010\u03b2 metabolism. The \u03b54 allele is less effective at clearing amyloid\u2010\u03b2, which contributes to its accumulation and plaque formation, a central mechanism in Alzheimer\u2019s pathology. In contrast, mutations in the APP gene lead to abnormal amyloid precursor protein processing and are more frequently implicated in familial cases. Patients with a family history of early-onset Alzheimer\u2019s often worry about their own risk. In sporadic Alzheimer\u2019s, although the disease typically appears later in life, carrying the APOE \u03b54 allele significantly increases the risk. Clinically, Alzheimer\u2019s disease presents with progressive memory loss, executive dysfunction, and other cognitive deficits. Diagnosis is based on clinical assessment, supported by neuroimaging (MRI or PET scans) and sometimes cerebrospinal fluid biomarkers. Differential diagnoses include vascular dementia, frontotemporal dementia, and Lewy body dementia. Each can be differentiated based on clinical course, imaging patterns, and additional features (e.g., motor symptoms in Lewy body dementia). Current management includes cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and NMDA receptor antagonists (memantine) as first-line treatment. Non-pharmacologic interventions like cognitive therapy and caregiver support are also recommended. In pregnancy and lactation, pharmacologic management is limited due to potential safety concerns, so emphasis is on non-drug supportive measures. Option A (APP) is primarily associated with familial Alzheimer\u2019s rather than the sporadic form. Option B (Apolipoprotein E) is correct because the APOE \u03b54 allele significantly raises the risk of sporadic Alzheimer\u2019s. Options C and D are not provided. \u2022 The APOE \u03b54 allele is a well-established risk factor for sporadic Alzheimer\u2019s disease.  \u2022 Mutations in the APP gene are implicated in familial early-onset Alzheimer\u2019s. Recent studies continue to show a strong association between the APOE \u03b54 allele and increased amyloid-\u03b2 deposition, reinforcing its role as a major risk factor for sporadic Alzheimer\u2019s. Emerging research is also focused on how modulating APOE expression might offer new therapeutic avenues.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Elderly patient presented to neurology clinic with complaint of progressive memory problem. The physician prescribed for him medication. After 2 weeks, he presented with nausea, anorexia, and diarrhea. Which of the following is the most likely prescribed medication?",
    "option_a": "Memantine",
    "option_b": "Rivastigmine",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "In elderly patients with progressive memory problems, Alzheimer\u2019s disease is a common consideration. First\u2010line pharmacotherapy for mild to moderate Alzheimer\u2019s includes cholinesterase inhibitors like rivastigmine, donepezil, and galantamine, while memantine (an NMDA receptor antagonist) is typically reserved for moderate to severe cases. Rivastigmine, in particular, is well known for its cholinergic mechanism which can increase gastrointestinal motility and secretions. Rivastigmine works by inhibiting both acetylcholinesterase and butyrylcholinesterase enzymes, thereby increasing acetylcholine levels in the brain. However, this increase is not confined to the central nervous system; the enhanced cholinergic activity in the gastrointestinal tract can lead to stimulation of muscarinic receptors, resulting in side effects such as nausea, anorexia, and diarrhea. The use of rivastigmine in Alzheimer\u2019s patients can improve cognitive function by compensating for the cholinergic deficit; however, the same mechanism leads to unwanted gastrointestinal symptoms. In clinical practice, these side effects are commonly encountered within the first few weeks of therapy, especially if the medication is titrated too rapidly. When an elderly patient on Alzheimer\u2019s medication presents with gastrointestinal symptoms, the differential includes side effects from cholinesterase inhibitors versus other causes of GI upset such as infections or concurrent medications. A careful review of the medication history and timing of symptoms (occurring shortly after initiation) helps establish the diagnosis. First-line management for mild to moderate Alzheimer\u2019s involves initiating a cholinesterase inhibitor such as rivastigmine at a low dose with gradual titration to minimize side effects. If gastrointestinal symptoms become severe, dose reduction or switching to an alternative medication (e.g., donepezil) may be considered. In the context of pregnancy or lactation, although Alzheimer\u2019s disease is rare in these populations, the safety data for cholinesterase inhibitors are limited and they should be prescribed only if the benefits clearly outweigh potential risks. Option A (Memantine) is generally used for moderate to severe Alzheimer\u2019s disease and is less associated with gastrointestinal side effects. Option B (Rivastigmine) is known for causing nausea, anorexia, and diarrhea due to its cholinergic mechanism, making it the correct answer. Options C and D are not provided, so they are not considered in this analysis. 1. Always titrate cholinesterase inhibitors slowly to reduce the risk of GI side effects. 2. Rivastigmine\u2019s dual inhibition (of both acetylcholinesterase and butyrylcholinesterase) is both its strength and source of adverse effects. Recent guidelines continue to support the use of cholinesterase inhibitors like rivastigmine for mild to moderate Alzheimer\u2019s disease, while current research focuses on balancing cognitive benefits with the tolerability of side effects. Studies have reinforced the importance of gradual dose escalation to mitigate adverse reactions.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Most psychiatric manifestation in AD",
    "option_a": "Apathy",
    "option_b": "Agitation",
    "option_c": "Disinhibition",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Alzheimer\u2019s disease (AD) is often accompanied by neuropsychiatric symptoms. Among these, apathy\u2014a lack of interest or motivation\u2014has been identified as one of the most common manifestations in AD. Neurodegeneration in regions such as the prefrontal cortex and limbic system, which are critical for motivation and emotional regulation, underlies the development of apathy in AD. Disruption of dopaminergic and other neurotransmitter systems further contributes to reduced initiative and engagement. In practice, patients with AD frequently exhibit apathy, which can be misinterpreted as depression. However, unlike major depressive disorder, apathy in AD typically lacks features like persistent sadness or feelings of guilt. Recognizing apathy is important because it directly affects patient engagement and overall function. Differential diagnoses include depression (characterized by mood disturbance and self-reproach), agitation (marked by restlessness and behavioral disturbances), and disinhibition (lack of social restraint). A careful clinical interview and the use of standardized scales can help differentiate apathy from these conditions. Management includes non-pharmacologic interventions such as structured activity programs, as well as pharmacotherapy in selected cases (e.g., stimulants or dopaminergic agents). There is no standard approved pharmacologic treatment specifically for apathy; thus, treatment is tailored to the individual. Special considerations for pregnancy and lactation are rarely applicable in Alzheimer\u2019s disease due to the typical age group affected. Option A (Apathy) is correct, as it is the most frequently observed psychiatric manifestation in AD. Option B (Agitation) and Option C (Disinhibition) are also seen in AD but are less common compared to apathy. 1. Apathy is the most common neuropsychiatric symptom in Alzheimer\u2019s disease and is an early indicator of functional decline. 2. It is important to distinguish apathy from depression to avoid inappropriate treatment. Recent research and updated guidelines highlight the prevalence of apathy in AD and underscore its impact on quality of life and caregiver burden. There is an ongoing investigation into targeted therapies that could address the underlying neurochemical deficits contributing to apathy.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "MMSE Test the most covered domain.",
    "option_a": "Orientation",
    "option_b": "Memory",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "The Mini-Mental State Examination (MMSE) is a widely used screening tool for cognitive impairment that assesses several domains including orientation, memory, attention, language, and visuospatial skills. Among these, the domain of orientation typically has the highest weight. Cognitive decline is reflected in difficulties with orientation, which involves the ability to correctly identify time and place. Since orientation requires the integration of multiple cognitive processes and brain regions, deficits here are a sensitive marker of global cognitive impairment. In patients with suspected dementia or other cognitive disorders, poor performance on orientation questions (which can be up to 10 points of the MMSE score) often correlates with more widespread cognitive dysfunction. This makes the orientation domain a critical part of the MMSE assessment. Differentiating cognitive domains is essential in the workup of dementia. While memory impairment is a hallmark of Alzheimer\u2019s disease, the MMSE places significant emphasis on orientation because impairment in this domain is more prevalent and easier to quantify in early stages of cognitive decline. The MMSE score assists clinicians in determining the need for further evaluation and in monitoring disease progression. In cases where cognitive screening is required for special populations such as pregnant or lactating women with cognitive complaints (rare scenarios), alternative or additional assessments may be considered due to the potential impacts of stress and hormonal changes on cognition. Option A (Orientation) is correct because the orientation section of the MMSE covers up to 10 points (5 for time and 5 for place), making it the most heavily weighted section compared to memory, which typically covers fewer points. Option B (Memory) is important but does not constitute the most covered domain within the MMSE. 1. The orientation section of the MMSE is crucial and heavily weighted, often providing early clues to a diagnosis of dementia. 2. A decline in orientation is an important red flag for global cerebral dysfunction. While the MMSE remains a cornerstone in cognitive screening, recent research emphasizes its strengths and limitations. Newer cognitive assessment tools are being developed to address some of the MMSE\u2019s shortcomings, yet its emphasis on orientation remains validated by current clinical practice and evidence.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Patient elderly poor oral intake with one week history of ongoing infection. what is the most likely cause.",
    "option_a": "Systemtic",
    "option_b": "Vascular",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "In elderly patients, especially those with preexisting conditions or limited oral intake, systemic infections are a common precipitant of clinical deterioration. Poor oral intake in the setting of an acute infection often reflects the systemic impact of the illness rather than a localized (e.g., vascular) pathology. Systemic infections trigger a cascade of inflammatory responses with the release of cytokines, leading to fever, anorexia, and metabolic imbalances. In the elderly, these processes are amplified, often resulting in significant reduction in appetite and overall intake. This systemic inflammatory response can further complicate preexisting comorbidities. An elderly patient with a one-week history of infection and poor oral intake is most likely experiencing the systemic effects of infection, which may also predispose them to dehydration and further complications like delirium. Unlike vascular events, which typically present with sudden focal deficits, systemic infections present more gradually with constitutional symptoms. In such cases, the differential diagnosis might include delirium due to systemic infection, dehydration, and possibly medication-induced anorexia. Vascular causes, such as stroke, usually present with acute focal neurological deficits rather than a week-long history of infection and poor oral intake. Laboratory tests, imaging, and careful history-taking help differentiate these conditions. Management involves prompt treatment of the infection with appropriate antibiotics, supportive care including hydration and nutritional support, and monitoring for complications such as delirium. In elderly patients, close monitoring is essential. In pregnant or lactating patients, the choice of antibiotics must be guided by safety profiles, ensuring that the benefits to the mother outweigh any potential risks to the fetus or infant. Option A (Systemtic) is correct as it points toward the systemic impact of infection leading to poor oral intake. Option B (Vascular) would imply a stroke or other vascular event, which is less consistent with the described gradual onset and systemic symptoms. Options C and D are not provided. 1. Infections in the elderly often present with non-specific symptoms, including poor oral intake and confusion. 2. Systemic inflammatory responses can lead to significant morbidity, emphasizing the need for prompt and aggressive management. Recent research underscores the importance of early recognition and treatment of systemic infections in the elderly to prevent complications such as dehydration and delirium. Updated guidelines stress individualized management plans, particularly in vulnerable populations, including careful selection of antibiotics in pregnant and lactating women when applicable.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Fatigue in daytime and increased sleepiness in Alzheimer\u2019s is due to.",
    "option_a": "Atrophy in subthalamic nuclei",
    "option_b": "Disturbance in serotonin pathway",
    "option_c": "Decrease glucose level",
    "option_d": "Suprachiasmatic nucleus degeneration",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Dementia",
    "explanation": "The suprachiasmatic nucleus (SCN) serves as the master clock of the body, regulating circadian rhythms and the sleep-wake cycle. In Alzheimer\u2019s disease (AD), disturbances in sleep architecture and increased daytime sleepiness are common, and degeneration of the SCN has been implicated as a key factor. In AD, neurodegenerative changes occur in several brain regions, including the SCN. Loss or degeneration of SCN neurons disrupts normal circadian signaling pathways, leading to sleep fragmentation, disrupted melatonin secretion, and ultimately increased daytime sleepiness and fatigue. This mechanistic insight is supported by neuropathological studies that document SCN involvement in AD progression. Patients with AD often exhibit sundowning, fragmented nocturnal sleep, and excessive daytime sleepiness, all of which are clinically correlated with the impaired functioning of the SCN. This disruption in circadian rhythm not only worsens cognitive deficits but also impacts overall quality of life. Differential diagnoses include primary sleep disorders (e.g., obstructive sleep apnea, narcolepsy) and other neurodegenerative conditions affecting sleep. Evaluation typically involves a detailed history, sleep questionnaires, and possibly polysomnography. Neuroimaging can support the diagnosis of AD, though the association with SCN degeneration is made more through neuropathological studies and clinical correlation. Management focuses on improving sleep hygiene, behavioral interventions, and, when indicated, pharmacologic treatment such as melatonin. First-line strategies include structured routines and environmental modifications (e.g., increased exposure to natural light). In some cases, low-dose melatonin is considered. Special considerations in pregnancy and lactation are usually not relevant for AD, as it predominantly affects older adults. However, for similar sleep disturbances in younger populations, non-pharmacological approaches are preferred. Option A (Atrophy in subthalamic nuclei) is not associated with circadian regulation. Option B (Disturbance in serotonin pathway) has a role in mood and sleep but is not the primary cause of the specific daytime fatigue seen in AD. Option C (Decrease glucose level) is not a recognized primary mechanism for sleepiness in AD. Option D (Suprachiasmatic nucleus degeneration) is supported by evidence as a significant contributor to the circadian dysregulation observed in AD. 1. The SCN is the body\u2019s master circadian clock, and its degeneration leads to significant sleep-wake disturbances in AD. 2. Daytime sleepiness and nighttime restlessness in AD are often reflections of disrupted circadian rhythms. 3. Non-pharmacologic strategies including light therapy and structured routines can be beneficial. Recent studies emphasize the role of SCN degeneration in AD-related sleep disturbances and promote the use of chronotherapeutic interventions (like timed light exposure and melatonin) to partially restore circadian rhythm. Ongoing research is examining novel strategies to preserve SCN function in neurodegenerative diseases.",
    "exam_year": "2024",
    "exam_type": "Part I"
  }
]